(Deamino-Cys1,β-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin trifluoroacetate salt
(Deamino-Cys1,β-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin trifluoroacetate salt structure
|
Common Name | (Deamino-Cys1,β-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin trifluoroacetate salt | ||
|---|---|---|---|---|
| CAS Number | 136105-89-0 | Molecular Weight | 1054.21000 | |
| Density | 1.56g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C45H63N15O11S2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Arginine vasopressin enhances pHi regulation in the presence of HCO3- by stimulating three acid-base transport systems.
Nature 337(6208) , 648-51, (1989) Growth factors raise intracellular pH (pHi) by stimulating Na+/H+ exchange in the absence of HCO3-. In mutant cells that lack the Na+/H+ exchange activity, this alkalinization does not occur, and the cells do not proliferate without artificial elevation of pH... |
|
|
Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.
Circulation 107(18) , 2313-9, (2003) Vasodilatory shock is a potentially lethal complication of severe disease in critically ill patients. Currently, catecholamines are the most widely used vasopressor agents to support blood pressure, but loss of catecholamine pressor effects is a well-known cl... |
|
|
Regulation of cyclooxygenase expression by vasopressin in rat renal medulla.
Endocrinology 145(3) , 1402-9, (2004) The antagonism between prostaglandin and vasopressin represents a classic negative feedback loop. It is not clear whether cyclooxygenase (COX)-2 and/or COX-1 expression is involved in elevated prostaglandin production stimulated by vasopressin in vivo. In the... |
|
|
A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary.
Endocrinology 129 , 1107-1109, (1991) The biological activity of a new synthetic analog of vasopressin, deamino[D-3-(3'-pyridyl)-Ala2, Arg8] vasopressin, was assessed in a number of assays. Antidiuretic (V2) and vasoconstrictor (V1), agonist and antagonist activities were assessed in rats in vivo... |
|
|
Gastrointestinal absorption and plasma clearance rates of [D-Arg8]vasopressin analogues in the rat.
Peptides 15 , 809, (1994) The gastrointestinal absorption of a series of vasopressin (VP) analogues with enhanced enzymatic stability was determined in chronically catheterized, conscious rats. The following peptides were used: [Mpa1,D-Arg8]vasopressin (dDAVP), [Mpa1,Asn4,D-Arg8]VP, [... |
|
|
Structure--function studies of vasopressin analogues with D-3 pyridyl-alanine in position 2.
Peptides 16 , 389-393, (1995) A number of analogues of vasopressin, incorporating the substitution of D-3'-(pyridyl)-alanine in position 2, were synthesized and tested for antidiuretic (V2), vasoconstrictor (V1a) and ACTH secretory (V1b; pituitary) activities. One analogue, deamino-[D-3'-... |
|
|
Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor.
Eur. J. Pharmacol. 401 , 289-296, (2000) Vasopressin V(2) receptors at high-density and V(1B) receptors are candidates for the V(2)-like receptor, which evokes an increase in [Ca(2+)](i) when stimulated by the vasopressin V(2) receptor agonist 1-desamino-8-D-arginine vasopressin (dDAVP) in kidney in... |